Phase II Study of Docetaxel +/- Nintedanib in Breast Cancer

Patients will be stratified at randomization according to first-line chemotherapy / Second-line chemotherapy for metastatic or locally recurrent breast cancer

Treatment until progression or unacceptable toxicity Visits are planned every 3 weeks during treatment and every 3 months after end of treatment or patient's withdrawal

Inclusion criteria

• Age ≥ 18 years old
• Histologically or cytologically confirmed adenocarcinoma of the breast
• Locally recurrent or metastatic disease
• HER 2 negative status
• Requiring a first or a second-line chemotherapy for locally recurrent or metastatic disease.
• Prior first line chemotherapy not containing Docetaxel
• Measurable or evaluable disease according to RECIST 1.1 criteria
• Allowed prior chemotherapy as follows :

• Docetaxel in the neoadjuvant or adjuvant setting is allowed provided that relapse has been observed more than 12 months after the end of docetaxel treatment
• Bevacizumab in 1st line is allowed with a wash-out of 4 weeks, with recovery to NCI-CTCAE v3.0 toxicity
• ECOG performance status 0-1
• Adequate bone marrow, hepatic and renal functions as evidence by the following:

• Hemoglobin ≥ 10 G/100 mL
• Neutrophils count ≥ 1500 /mm3
• Platelets ≥ 100 000 /mm3
• Total bilirubin ≤ ULN (ULN:Upper Limit of Normal)
• SGOT/SGPT ≤ 1.5 x ULN (≤ 2.5 x ULN in case of hepatic metastasis)
• Serum alkaline phosphatase ≤ 2.5 x ULN
• Creatinin clearance ≥ 45 ml/min or creatinin ≤ 1.5 x ULN
• Proteinuria < CTCAE grade 2
• Coagulation parameters: International normalised ratio (INR) ≤ 2, prothrombin time (PT) and partial thromboplastin time (PTT) ≤ 50% of deviation of institutional ULN
• Effective contraception for patients (male and female) with reproductive potential during their entire participation in the study and during 3 months after the last administration of Nintedanib or Docetaxel
• Negative pregnancy test (serum beta-HCG) performed within 1 week prior to start of study treatment in females with reproductive potential
• Patient covered by government health insurance
• Signed and dated written informed consent prior to admission to the study in accordance with ICH-GCP guidelines and to the local legislation

Exclusion criteria

• Concomitant hormone therapy for metastatic breast cancer
• Patients with dysphagia, or inability to swallow the tablets
• Other serious illness or medical conditions: Cardiac disease
• Unstable diabetes
• Uncontrolled hypercalcemia
• Pregnancy or breast feeding woman
• Unable for medical follow-up (geographic, social or mental reasons)
• Prior treatment with Nintedanib or any other VEGFR inhibitor
• Known hypersensitivity to the trial drugs , to their excipients, to peanut, to soya or to contrast media
• Contra indication to the use of the backbone treatment and to the comparator
• Active brain metastases (e.g. stable for <4 weeks, no adequate previous treatment with radiotherapy, symptomatic, requiring treatment with anti-convulsants; dexamethasone therapy will be allowed if administered as stable dose for at least one month before randomisation)
• Leptomeningeal disease
• Radiographic evidence of cavitary or necrotic tumors
• Centrally located tumors with radiographic evidence (CT or MRI) of local invasion of major blood vessels
• History of clinically significant haemorrhagic or thromboembolic event in the past 6 months
• Known inherited predisposition to bleeding or thrombosis
• Significant cardiovascular diseases ( i.e. uncontrolled hypertension, unstable angina, history of infarction within the past 12 months prior to start of study treatment, congestive heart failure > NYHA II, serious cardiac arrhythmia, pericardial effusion)
• Other malignancies within the past 5 years other than basal cell skin cancer or carcinoma in situ of the cervix
• Active serious infections in particular if requiring systemic antibiotic or antimicrobial therapy
• Active or chronic hepatitis C and/or B infection
• Active alcohol or drug abuse
• Significant weight loss (> 10% of BW) within past 6 months prior to inclusion into the trial